You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 21, 2024

Details for Patent: 11,648,244


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 11,648,244 protect, and when does it expire?

Patent 11,648,244 protects AUSTEDO XR and AUSTEDO and is included in two NDAs.

Protection for AUSTEDO XR has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has forty-four patent family members in twenty-four countries.


Recent additions to Drugs Protected by US Patent 11,648,244

These patents are from the daily update and have not yet been integrated into the regular database
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Product Substance Delist Req. Patent Expiration Usecode Patented / Exclusive Use
Teva AUSTEDO XR deutetrabenazine TABLET, EXTENDED RELEASE 216354 Feb 17, 2023 RX Yes ⤷  Sign Up ⤷  Sign Up U-1995 TREATMENT OF TARDIVE DYSKINESIA
Teva AUSTEDO XR deutetrabenazine TABLET, EXTENDED RELEASE 216354 Jul 1, 2024 RX Yes ⤷  Sign Up ⤷  Sign Up U-1995 TREATMENT OF TARDIVE DYSKINESIA
Teva AUSTEDO XR deutetrabenazine TABLET, EXTENDED RELEASE 216354 May 29, 2024 RX Yes ⤷  Sign Up ⤷  Sign Up U-1995 TREATMENT OF TARDIVE DYSKINESIA
Teva AUSTEDO XR deutetrabenazine TABLET, EXTENDED RELEASE 216354 May 29, 2024 RX No ⤷  Sign Up ⤷  Sign Up U-1995 TREATMENT OF TARDIVE DYSKINESIA
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Type >RLD >Patent No. >Product >Substance >Delist Req. >Patent Expiration >Usecode >Patented / Exclusive Use

Drugs Protected by US Patent 11,648,244

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Teva AUSTEDO XR deutetrabenazine TABLET, EXTENDED RELEASE;ORAL 216354-001 Feb 17, 2023 RX Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Teva AUSTEDO XR deutetrabenazine TABLET, EXTENDED RELEASE;ORAL 216354-002 Feb 17, 2023 RX Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Teva AUSTEDO XR deutetrabenazine TABLET, EXTENDED RELEASE;ORAL 216354-008 Jul 1, 2024 RX Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Teva AUSTEDO XR deutetrabenazine TABLET, EXTENDED RELEASE;ORAL 216354-003 Feb 17, 2023 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Teva AUSTEDO XR deutetrabenazine TABLET, EXTENDED RELEASE;ORAL 216354-004 May 29, 2024 RX Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Teva AUSTEDO XR deutetrabenazine TABLET, EXTENDED RELEASE;ORAL 216354-005 May 29, 2024 RX Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 11,648,244

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 103876 ⤷  Sign Up
Australia 2016229949 ⤷  Sign Up
Australia 2021204740 ⤷  Sign Up
Canada 2978006 ⤷  Sign Up
Canada 3236214 ⤷  Sign Up
Chile 2017002223 ⤷  Sign Up
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.